Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of $130.89 billion. The enterprise value is $176.35 billion.
Important Dates
The last earnings date was Tuesday, April 29, 2025, before market open.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | May 9, 2025 |
Share Statistics
Pfizer has 5.69 billion shares outstanding. The number of shares has increased by 0.97% in one year.
| Current Share Class | 5.69B |
| Shares Outstanding | 5.69B |
| Shares Change (YoY) | +0.97% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 66.38% |
| Float | 5.68B |
Valuation Ratios
The trailing PE ratio is 16.64 and the forward PE ratio is 7.89. Pfizer's PEG ratio is 1.50.
| PE Ratio | 16.64 |
| Forward PE | 7.89 |
| PS Ratio | 2.02 |
| Forward PS | 2.05 |
| PB Ratio | 1.40 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.70 |
| P/OCF Ratio | 9.38 |
| PEG Ratio | 1.50 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.56, with an EV/FCF ratio of 15.72.
| EV / Earnings | 22.37 |
| EV / Sales | 2.82 |
| EV / EBITDA | 7.56 |
| EV / EBIT | 10.72 |
| EV / FCF | 15.72 |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.69.
| Current Ratio | 1.26 |
| Quick Ratio | 0.88 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | 2.55 |
| Debt / FCF | 5.56 |
| Interest Coverage | 5.57 |
Financial Efficiency
Return on equity (ROE) is 8.62% and return on invested capital (ROIC) is 6.52%.
| Return on Equity (ROE) | 8.62% |
| Return on Assets (ROA) | 4.79% |
| Return on Invested Capital (ROIC) | 6.52% |
| Return on Capital Employed (ROCE) | 9.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.29 |
| Inventory Turnover | 1.47 |
Taxes
| Income Tax | -510.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.85% in the last 52 weeks. The beta is 0.50, so Pfizer's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -17.85% |
| 50-Day Moving Average | 24.19 |
| 200-Day Moving Average | 26.74 |
| Relative Strength Index (RSI) | 46.98 |
| Average Volume (20 Days) | 49,731,686 |
Short Selling Information
The latest short interest is 115.16 million, so 2.03% of the outstanding shares have been sold short.
| Short Interest | 115.16M |
| Short Previous Month | 97.49M |
| Short % of Shares Out | 2.03% |
| Short % of Float | 2.03% |
| Short Ratio (days to cover) | 2.00 |
Income Statement
In the last 12 months, Pfizer had revenue of $62.46 billion and earned $7.88 billion in profits. Earnings per share was $1.38.
| Revenue | 62.46B |
| Gross Profit | 46.49B |
| Operating Income | 16.45B |
| Pretax Income | n/a |
| Net Income | 7.88B |
| EBITDA | 23.32B |
| EBIT | 16.45B |
| Earnings Per Share (EPS) | $1.38 |
Full Income StatementBalance Sheet
The company has $17.32 billion in cash and $62.40 billion in debt, giving a net cash position of -$45.08 billion or -$7.93 per share.
| Cash & Cash Equivalents | 17.32B |
| Total Debt | 62.40B |
| Net Cash | -45.08B |
| Net Cash Per Share | -$7.93 |
| Equity (Book Value) | 90.64B |
| Book Value Per Share | 15.89 |
| Working Capital | 9.41B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $13.99 billion and capital expenditures -$2.77 billion, giving a free cash flow of $11.22 billion.
| Operating Cash Flow | 13.99B |
| Capital Expenditures | -2.77B |
| Free Cash Flow | 11.22B |
| FCF Per Share | $1.97 |
Full Cash Flow StatementMargins
Gross margin is 74.42%, with operating and profit margins of 26.33% and 12.62%.
| Gross Margin | 74.42% |
| Operating Margin | 26.33% |
| Pretax Margin | 11.82% |
| Profit Margin | 12.62% |
| EBITDA Margin | 37.34% |
| EBIT Margin | 26.33% |
| FCF Margin | 17.96% |
Dividends & Yields
This stock pays an annual dividend of $1.72, which amounts to a dividend yield of 7.47%.
| Dividend Per Share | $1.72 |
| Dividend Yield | 7.47% |
| Dividend Growth (YoY) | 2.41% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 124.35% |
| Buyback Yield | -0.97% |
| Shareholder Yield | 6.49% |
| Earnings Yield | 6.00% |
| FCF Yield | 8.55% |
Dividend DetailsAnalyst Forecast
The average price target for Pfizer is $30.36, which is 31.87% higher than the current price. The consensus rating is "Hold".
| Price Target | $30.36 |
| Price Target Difference | 31.87% |
| Analyst Consensus | Hold |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | -1.87% |
| EPS Growth Forecast (5Y) | 13.81% |
Stock ForecastsStock Splits
The last stock split was on July 1, 1999. It was a forward split with a ratio of 3:1.
| Last Split Date | Jul 1, 1999 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Pfizer has an Altman Z-Score of 2.22 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.22 |
| Piotroski F-Score | 8 |